Status:
UNKNOWN
Bruxism Xeomin® Intervention Trial
Lead Sponsor:
Dominik Ettlin
Collaborating Sponsors:
Merz Pharmaceuticals
Conditions:
Sleep Bruxism, Adult
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to test whether severe masticatory muscle spasms during sleep (e.g. teeth clenching and grinding, known as "bruxism" in technical jargon) demonstrably decrease after appli...
Detailed Description
Bruxism is a prevalent condition that differentially burdens individuals. The overall objective of this pilot study is to measure the effects of BTX-A (Xeomin®) injections into bilateral masseter musc...
Eligibility Criteria
Inclusion
- Age 18-90 years;
- patients complaining of bruxism and/or bruxism-related symptoms.
- Sufficient knowledge of German to understand the patient information and the trial arrangement.
Exclusion
- Contraindications for Xeomin® treatment such as generalized disorders of muscle activity (myasthenia gravis, Lambert-Eaton-Rooke syndrome);
- documented hypersensitivity to one of the components,
- local infection of the injection sites;
- intake of anticoagulants or muscle relaxing medications;
- recreational drugs.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04792398
Start Date
May 1 2021
End Date
June 1 2023
Last Update
March 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Zurich, Center of Dental Medicine
Zurich, Switzerland, 8032